

Stelis Biopharma signs research collaboration agreement with Bio-Scaffold International

23 October 2013 | News | By BioSpectrum Bureau

Stelis Biopharma signs research collaboration agreement with Bio-Scaffold International



This collaboration is expected to research and develop BMP and stem cell loaded 3D printed devices for various applications in orthopaedics, cosmetology or plastic and reconstructive surgery and dentistry.

The company said that the research will be jointly directed by Dr Anand Iyer, CEO, Stelis Biopharma and Dr Margam Chandrasekaran, CEO & chief scientist, Bio-scaffold International.

It is said that each company will bear the cost of its contribution to this joint research collaboration.

BSI is a pioneer in the application of 3D printing technology for the development of novel, biocompatible scaffolds.

Stelis is a biotechnology company whose research and development efforts include the development of drug and stem cell loaded devices for the treatment of various medical conditions.

Scientists from Stelis and BSI have developed a framework for initial research collaboration which would include working on multiple areas such as BMP-2/7 heterodimer loaded scaffold for orthopaedic applications and BMP2/ BMP7 loaded scaffolds for spinal fusion.

Dr Iyer and Dr Chandrasekaran said that this joint collaboration would help harness the synergies of the two companies in

advancing the development of novel 3D printed devices for effectively treating various conditions in the orthopaedic, orthodontic oral or maxillofacial and plastic or reconstructive arena.